Drug profile · INN
erythromycin gluceptate
ILOTYCIN GLUCEPTATE
erythromycin gluceptate (ILOTYCIN GLUCEPTATE) is a bacterial 70s ribosome inhibitor. Route of administration: injection. Current US regulatory status: approved.
Drug details — erythromycin gluceptate
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
erythromycin gluceptate (ILOTYCIN GLUCEPTATE) is a bacterial 70s ribosome inhibitor. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Bacterial 70S ribosome inhibitor
Primary target: Bacterial 70S ribosome
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is erythromycin gluceptate?
erythromycin gluceptate (ILOTYCIN GLUCEPTATE) is a bacterial 70s ribosome inhibitor. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for erythromycin gluceptate?
ILOTYCIN GLUCEPTATE is a marketed brand name for erythromycin gluceptate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of erythromycin gluceptate?
erythromycin gluceptate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.